The hidden condition: Status, challenges, and opportunities in the management of enlarged prostate for managed care

American Journal of Managed Care

Volumn 12, Issue SUPPL. 4, 2006, Pages

  Naslund, Michael James ^a   Chiao, Evelyn ^b   Black, Libby ^b   Eaddy, Michael T ^b  

^a Maryland Prostate Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEALTH CARE COST; HUMAN; HYPOTENSION; LIBIDO DISORDER; MANAGED CARE; MEDICAL LITERATURE; MINIMALLY INVASIVE SURGERY; PHYTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URETHRA DISEASE; URINE RETENTION; VASODILATATION;

HUMANS; MALE; MANAGED CARE PROGRAMS; PROSTATIC HYPERPLASIA; UNITED STATES;

EID: 33645465632     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project. Eur Urol. 2002;42:323-328.
2. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matched the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-246.
3. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary sympoms. J Urol. 1993;150:85-89.
4. Eri LM, Tveter KJ. Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Drugs Aging. 1997;10:107-118.
5. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256-1261.
6. US Census Bureau. US Interim Projections by Age, Sex, Race, and Hispanic Origin. Available at: http://www. census.gov/ipc/www/usinterimproj/. Accessed December 20, 2005.
7. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717.
8. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003; 44:637-649.
9. Hellstrom WJ. Benign prostatic hyperplasia, sexual function, and overall evaluation of the male patient. J Am Osteopath Assoc. 2004;104(2 suppl 2):S5-S10.
10. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005; 173:1309-1313.
11. Roehrborn CG, McConnell JD, Barry MJ, et al; for the Benign Prostatic Hyperplasia (BPH) Guideline Update Panel of the American Urological Association Education and Research, Inc. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). 2003.
12. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 2000;163:107-113.
13. Rhodes T, Girman CJ, Jacobson SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161:1174-1179.
14. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol. 2001;3:187-192.
15. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481-487.
16. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol. 1999;6:819-822.
17. Speakman MJ, Kirby KS, Joyce A, Abrams P, Pocock R; The British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93:985-990.
18. Naderi N, Mochtar CA, de la Rosette JJ. Real life practice in the management of benign prostatic hyperplasia. Curr Opin Urol. 2004;14:41-44.
19. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics. 2001; 19:131-153.
20. Avodart [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
21. Flomax [package insert]. Ridgefield, Conn: Boehringer Ingelheim; 2005.
22. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
23. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338:557-563.
24. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA 3001, ARIA 3002, ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of the 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-441.
25. Croom KF, Wagstaff AJ. Management of benign prostatic hyperplasia. Dis Manage Health Outcomes. 2004; 12:337-350.
26. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 2004;45:620-626; discussion 626-627.
27. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha reductase inhibitor dutasteride. Eur Urol. 2003;44:461-466.